As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his…

It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will…

Returns on R&D among the world's largest pharma companies are still in free fall with no signs of a recovery, says Deloitte.

Let’s be honest, 2016 was a mess of year, and one that many of us will be happy to see the back of. It saw the loss of a series of beloved actors, actresses…

uniQure plans to cut projects and R&D staff to reduce costs as it strives to bring its next product to market.

Two months ago Novavax announced that its Phase III RSV F vaccine flopped fantastically, and now, with a sense of inevitability, it has announced a “corporate…

An audible sigh of relief was heard this morning that, at last, the U.S. 2016 election is over. In the end, in what was an oft-controversial, hot-tempered and…

Canadian cancer biotech Oncolytics announced alongside its financials that its long-standing president and CEO, Brad Thompson, will be leaving the company “…

Allergan took an R&D hit this quarter as it emerged from analysts that a Phase II test of dermatology med VTP-38543, acquired as part of a $640 million…

Financials